The primary manifestation of the antiphospholipid antibody syndrome (APS) is thrombosis, which forms the core of the classification criteria for this syndrome. However, multiple other noncriteria ...

FDA approved triplet therapy for relapsed/refractory LBCL, including specific subtypes, for patients ineligible for auto-HSCT or CAR T-cell therapy. The therapy includes brentuximab vedotin, ...

In this open-label trial, a higher proportion of asymptomatic follicular lymphoma patients assigned to rituximab required no further treatment at nearly 15 years compared with those assigned to ...

Please provide your email address to receive an email when new articles are posted on . Learning from 2 decades of off-label rituximab use in systemic lupus erythematosus may point the way toward ...

Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent ...